⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VALN News
Valneva SE American Depositary Shares
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
globenewswire.com
VALN
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
globenewswire.com
VALN
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
globenewswire.com
VALN
Valneva Provides Update on IXCHIQ® in the United Kingdom
globenewswire.com
VALN
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
globenewswire.com
PFE
VALN
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
businesswire.com
VALN
PFE
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
globenewswire.com
VALN
Valency Selected for DOE's Genesis Mission to Accelerate Nuclear Power Research with AI Agents
prnewswire.com
VALN
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
globenewswire.com
VALN
Valneva Announces Successful Outcome of its Annual General Meeting
globenewswire.com
VALN